Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 13/20 | 0.56 |
| ▸ | MAOA | P21397 | 12/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13282888 | 0.83 | EIF2AK2 (0.84) | EIF2AK2MAPTMAOBMAOAKIF11 | |
| SCHEMBL3310832 | 0.81 | MAOB (0.58) | EIF2AK2MAOBMAOAKIF11DRD2 | |
| SCHEMBL15413967 | 0.81 | MAOB (0.85) | MAOBMAOA | |
| SCHEMBL1513178 | 0.80 | MAPT (0.53) | EIF2AK2MAPTMAOBMAOANPC1 | |
| SCHEMBL8882372 | 0.77 | MAPT (0.62) | MAPTMAOBMAOAKIF11NPC1 | |
| SCHEMBL3525548 | 0.77 | HRH3 (0.49) | EIF2AK2MAPTMAOBMAOAMAPK14 | |
| SCHEMBL15283124 | 0.77 | MAPT (0.49) | EIF2AK2MAPTMAOBMAOADRD2 | |
| SCHEMBL5469125 | 0.76 | HRH3 (0.45) | EIF2AK2MAOBMAOAMAPK14 | |
| SCHEMBL21758061 | 0.76 | HRH3 (0.62) | MAOBMAOADRD2NPC1MAPK14 | |
| SCHEMBL15414439 | 0.75 | EIF2AK2 (0.46) | EIF2AK2MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BIOPORT R&D, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1392317-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1392317-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100327-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BAK1, BAD, BAX | EIF2AK2 2146/4885MAPT 2956/4885MAOB 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.